Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience

Abstract Introduction Immune checkpoint inhibitor (ICI) pneumonitis causes substantial morbidity and mortality. Estimates of real-world incidence and reported risk factors vary substantially. Methods We conducted a retrospective review of 419 patients with advanced non-small cell lung cancer (NSCLC)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2023-11, Vol.28 (11), p.e1065-e1074
Hauptverfasser:	Altan, Mehmet, Soto, Felipe, Zhong, Linda L, Akhmedzhanov, Fechukwu O, Wilson, Nathaniel R, Zarifa, Abdulrazzak, Albittar, Aya A, Yang, Vincent, Lewis, Jeff, Rinsurongkawong, Waree, Jack Lee, J, Rinsurongkawong, Vadeerat, Zhang, Jianjun, Gibbons, Don L, Vaporciyan, Ara A, Jennings, Kristofer, Khawaja, Fareed, Faiz, Saadia A, Shannon, Vickie R, Shroff, Girish, Godoy, Myrna C B, Daver, Naval G, Gandhi, Saumil, Mendoza, Tito R, Naing, Aung, Daniel-MacDougall, Carrie, Heymach, John V, Sheshadri, Ajay
Format:	Artikel
Sprache:	eng
Schlagworte:	Bacterial pneumonia Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Care and treatment Chemotherapy Diagnosis Dosage and administration Humans Incidence Lung Cancer Lung cancer, Non-small cell Lung Diseases, Interstitial - complications Lung Neoplasms - drug therapy Monoclonal antibodies Patient outcomes Pneumonia Pneumonia - epidemiology Prevention Retrospective Studies Risk Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!